PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG ...

Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...

PTC will use the proceeds of this transaction to expand our splicing platform as well as to support commercial and development portfolio activities." "Huntington's Disease is a devastating ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

PTC said. Novartis had stopped, opens new tab the development of its Huntington's disease drug last year after concerns around potential nerve damage in patients. Novartis, which has been chasing ...